Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study
Open Access
- 1 January 2006
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Clinical Practice & Epidemiology in Mental Health
- Vol. 2 (1) , 14
Abstract
Patients with schizophrenia are at high risk of developing metabolic abnormalities. A prospective study focusing on metabolic disturbances in patients with schizophrenia, including an oral glucose tolerance test, is currently ongoing at our University Hospital and affiliate services. The prevalence of metabolic abnormalities at baseline was assessed in a cohort of 415 patients with schizophrenia. The sample was divided into 4 groups according to duration of illness: first-episode patients (20 years). Metabolic abnormalities were already present in first-episode patients, and considerably increased with increasing duration of illness. When compared to the general population matched for age and gender, much higher rates of the metabolic syndrome (MetS) and diabetes were observed for patients with schizophrenia. For MetS, the increase over time was similar to that of the general population. In contrast, the difference in the prevalence of diabetes in patients with schizophrenia and the general population dramatically and linearly increased from 1.6% in the 15–25 age-band to 19.2% in the 55–65 age-band. Thus, the current data suggest that on the one hand metabolic abnormalities are an inherent part of schizophrenic illness, as they are already present in first-episode patients. On the other hand, however, our results suggest a direct effect of the illness and/or antipsychotic medication on their occurence. The data underscore the need for screening for metabolic abnormalities in patients diagnosed with schizophrenia, already starting from the onset of the illness.Keywords
This publication has 51 references indexed in Scilit:
- Diabetic ketoacidosis associated with aripiprazoleDiabetic Medicine, 2005
- Metabolic syndrome and schizophreniaThe British Journal of Psychiatry, 2005
- New Onset of Diabetes Mellitus With ZiprasidoneThe Journal of Clinical Psychiatry, 2005
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005
- Atrial fibrillation: mortality, morbidity, and money; is that all? Importance and variability of burden measurementEuropean Heart Journal, 2004
- Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With SchizophreniaAmerican Journal of Psychiatry, 2003
- Report of the Expert Committee on the Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2003
- Changes in body mass index for individuals with and without schizophrenia, 1987–1996Schizophrenia Research, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Excess mortality of schizophreniaThe British Journal of Psychiatry, 1997